Goodwill

3 Months Ended

Mar. 31, 2025

NOTE 6 – Goodwill:

Changes in the carrying amount of goodwill for the period ended March 31, 2025, were as follows:


	United States		Europe		International Markets		Other				Total
	United States		Europe		International Markets		Teva’s API		Medis		Total
	(U.S. $ in millions)
Balance as of December 31, 2024 (1)	$	5,732	$	8,075	$	1,110	$	—	$	232	$	15,147

Other changes during the period:
Translation differences and other		—		241		64		—		24		330

Balance as of March 31, 2025 (1)	$	5,732	$	8,316	$	1,174	$	—	$	256	$	15,477

(1)	Cumulative goodwill impairment as of March 31, 2025 and December 31, 2024, was each approximately $29.6 billion.

Teva operates its business through three reporting segments: United States, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva’s production and sale of APIs to third parties (“Teva API”) and an

out-licensing

platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Teva’s API and Medis reporting units are included under “Other” in the table above. See note 15 for additional segment information.

Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva’s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (“WACC”), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva’s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future.

First Quarter Developments

During the first quarter of 2025, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of March 31, 2025. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed.